|

CC-99282 Clinical Trials

1 actively recruiting trial across 1 location

No change since July 2026

Also known as: BMS-986369

Pipeline

Phase 2: 1

Top Sponsors

  • M.D. Anderson Cancer Center1

Indications

  • Tumor1
  • Follicular Lymphoma1
  • Cancer1

Houston, Texas1 trial

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.